Evommune, Inc.
NYSE:EVMNBiotechnology
-$0.17 today
- Market cap
- $290.28M
- Beta
- 0.10
- P/E (TTM)
- -9.1
- EPS (TTM)
- -$2.26
Volume 0.90M
Average 0.38M
EVMN EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Evommune, Inc.NYSE: EVMN
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q1 FY2026 EBITDA was -$21.33M, compared with -$14.18M a year earlier. Trailing-twelve-month EBITDA was -$74.62M.
Context
- EBITDA amounted to 519.1% of revenue in FY2025, down 416.4 pp from a year earlier.
- EBITDA grew in size in 2 of the last 2 fiscal years.
- FY2025 was the largest annual figure in the 3 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 6 analysts of -$18.86M (+72.0%) for the fiscal year ending Dec 2026, a step up from the -3.0% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$21.33M+23.7% QoQ
- Last fiscal yearDec 2025
- -$67.48M-3.0% YoY
- LTMMar 2026
- -$74.62M— YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -50.4% | -78.9% | -28.4 pp |
| 1 year | -3.0% | +72.0% | +75.1 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (67.48M) USD
- Year-over-year change
- -3.0%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (67.48M) | -3.0% |
| FY2024 | 2024-12-31 | (65.49M) | -98.5% |
| FY2023 | 2023-12-31 | (33M) | — |
EBITDA vs competitors
How EVMN compares with its peers on the latest reported figures
- EVMN's LTM Mar 2026 EBITDA of -$74.62M is the 7th highest of the 10 companies compared; the peer median is -$33.82M.
- EBITDA amounts to 746.2% of revenue for EVMN, versus a peer median of 94.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $274.03M | +696.5% | +33.4% | 94.3% | |
FTREFortrea Holdings Inc. | LTM Jun 2026 | $81.2M | +109.5% | — | 3.0% |
| LTM Sep 2026 | $57.08M | +205.8% | — | 21.5% | |
| LTM Mar 2026 | -$22.06M | +62.9% | — | 28.2% | |
| LTM Mar 2026 | -$33.82M | +24.4% | — | 117.0% | |
CLYMClimb Bio, Inc. | LTM Mar 2026 | -$52.66M | +43.4% | — | — |
EVMNEvommune, Inc. | LTM Mar 2026 | -$74.62M | — | — | 746.2% |
ARTVArtiva Biotherapeutics, Inc. | LTM Mar 2026 | -$84.44M | -35.4% | — | — |
| LTM Mar 2026 | -$147.92M | -653.3% | — | 97.9% | |
| LTM Mar 2026 | -$260.06M | -79.4% | — | 3415.1% | |
| Peer median (excluding EVMN) | -$33.82M | +43.4% | +33.4% | 94.3% | |
Competitors are the stored peer set for EVMN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|
| Revenue | 5M | 7M | 13M |
| Cost of Revenue | 1M | 1.29M | 0 |
| Gross Profit | 4M | 5.71M | 13M |
| Gross Margin | 80.0% | 81.6% | 100.0% |
| Research & Development | 32M | 64.24M | 74.04M |
| Selling, General & Admin | 9.85M | 11.48M | 20.03M |
| Operating Expenses | 41.85M | 75.73M | 94.07M |
| Depreciation & Amortization | 1M | 1.29M | 1.39M |
| EBITDA | (33M) | (65.49M) | (67.48M) |
| EBITDA Margin | -659.9% | -935.5% | -519.1% |
| Operating Income | (37.85M) | (70.01M) | (81.07M) |
| Operating Margin | -757.0% | -1000.2% | -623.6% |
| Interest Income | 3.86M | 3.24M | 3.32M |
| Interest Expense | 58K | 34K | 0 |
| Other Income / Expenses | 3.8M | 3.2M | 12.2M |
| Income Before Tax | (34.05M) | (66.81M) | (68.87M) |
| Pre-Tax Margin | -681.1% | -954.4% | -529.8% |
| Income Tax Expense | 0 | 0 | 0 |
| Net Income | (34.05M) | (66.81M) | (68.87M) |
| Net Margin | -681.1% | -954.4% | -529.8% |
| EPS (Basic) | (1.13) | (2.27) | (2.18) |
| EPS (Diluted) | (1.13) | (2.27) | (2.18) |
| Weighted Avg Shares | 30.08M | 30.08M | 31.52M |
| Weighted Avg Shares (Diluted) | 30.08M | 30.08M | 31.52M |
Evommune, Inc.
NYSE:EVMN
Intrinsic Alpha fair value
Locked
Current Price
$7.02
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.